WuXi Biologics is trading 4.13% down at HK$42.76, with no specific catalyst established in the available evidence. - Fresenius announced on November 2 that it can select up to 37 biosimilar candidates for development; WuXi will be paid on a fee-for-service basis. Reuters confirmed the agreement. - Biotech-sector weakness may be a backdrop, but evidence does not link it specifically to the decline. No trading-volume data was supplied, so activity cannot be assessed.